Brief: Oasmia Buys Global Development And Commercialization Rights For Cantrixil

Vivesto AB

01/03/2021 06:02

March 1 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * OASMIA ACQUIRES GLOBAL DEVELOPMENT AND COMMERCIALIZATION
RIGHTS
FOR CANTRIXIL, A CLINICAL STAGE, OVARIAN CANCER PROGRAM
    * SIGNED AN AGREEMENT WITH KAZIA THERAPEUTICS TO ACQUIRE
EXCLUSIVE
GLOBAL DEVELOPMENT RIGHTS FOR CANTRIXIL
    * WILL ACQUIRE LICENSE FOR AN UPFRONT CASH CONSIDERATION OF
$4M,
DEVELOPMENT MILESTONES WORTH UP TO $42M AND CUMULATIVE
SALES-BASED ROYALTIES
    * AGREEMENT IS FIRST IN A SERIES OF PLANNED IN-LICENSING
DEALS AND
ACQUISITIONS TO EXPAND OASMIA'S ONCOLOGY PORTFOLIO
    * A PHASE II STUDY WITH CANTRIXIL IS EXPECTED TO BE
INITIATED IN
2022

Source text for Eikon:  ID:nMFN58Nx4n 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 587696600;))